Agenus (AGEN) Posts Earnings Results, Misses Expectations By $0.07 EPS

Agenus (NASDAQ:AGEN) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07), Bloomberg Earnings reports. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.30 million. Agenus’s revenue for the quarter was up 48.2% compared to the same quarter last year.

Shares of Agenus (AGEN) opened at $5.40 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. The stock has a market cap of $587.32, a P/E ratio of -4.89 and a beta of 1.50. Agenus has a 12-month low of $3.20 and a 12-month high of $6.19.

AGEN has been the subject of a number of research analyst reports. BidaskClub lowered shares of Agenus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, January 9th. Finally, ValuEngine upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Agenus currently has an average rating of “Buy” and an average price target of $5.81.

ILLEGAL ACTIVITY NOTICE: This article was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.

Leave a Reply